Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors | ReachRx